Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613869 | 1.00 | CTSK (0.32) | CTSKCA1CA2CA7 | |
| SCHEMBL94143 | 1.00 | CTSK (0.32) | CTSKCA1CA2CA7 | |
| SCHEMBL19160929 | 0.85 | CTSK (0.31) | CTSKCA1CA2CA7 | |
| SCHEMBL24540264 | 0.82 | — | — | |
| SCHEMBL4141652 | 0.77 | CA12 (0.32) | CA1CA2 | |
| SCHEMBL4141650 | 0.77 | CA12 (0.32) | CA1CA2 | |
| SCHEMBL17050367 | 0.77 | CA12 (0.32) | CA1CA2 | |
| SCHEMBL20824880 | 0.75 | CTSK (0.36) | CTSKCA1CA2CA7 | |
| SCHEMBL15927997 | 0.73 | — | — | |
| SCHEMBL9825498 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 748 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791466-A | Preparation method of radioactive probe precursor | 南京医科大学 | 2024-10-18 | — | — | CN | claimed |
| EP-4746968-A1 | PYRROLIDINE COMPOUNDS LP(A) LOWERING ACTIVITY | Eli Lilly and Company (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747236-A1 | PIPERIDINE, MORPHOLINE AND TETRAHYDRO-PYRIDAZINE COMPOUNDS WITH LP(A) LOWERING ACTIVITY | Eli Lilly and Company (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747232-A1 | PYRROLIDINE COMPOUNDS WITH LP(A) LOWERING ACTIVITY | Eli Lilly and Company (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739663-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4313980-B1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC (CA) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-4126682-A | 7-ACYL-3-(CARBOXYALKYL AND CARBAMOYLALKYL SUBSTITUTED OXADIAZOLYLTHIOMETHYL) CEPHALOSPORINS AND ANTIBACTERIAL COMPOSITIONS AND METHODS EMPLOYING THEM | SMITHKLINE CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
| US-4118490-A | ANTIBACTERIAL ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-4112086-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4103086-A | 8-Oxo-4-thia-1-azabicyclo (4.2.0)-oct-2-ene derivatives | SMITHKLINE CORPORATION (US) | 1978-07-25 | — | — | US | disclosed |
| US-4101656-A | 7β-Acylamino-3-(alkanesulfonamidoalkyl substituted tetrazolylthiomethyl) cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them | SMITHKLINE CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4093723-A | ANTIBIOTICS | SMITHKLINE CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4072674-A | FOR CEPHALOSPORIN CONGENERS | SMITHKLINE CORPORATION (US) | 1978-02-07 | — | — | US | disclosed |
| US-4048311-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4034092-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
| US-3947274-A | Silver halide photographic material containing an isourea derivative as antifoggant | FUJI PHOTO FILM CO., LTD. (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSK 50/4885CA1 213/4885CA2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.